Highlights

  • Integral Diagnostics Limited (ASX:IDX) reported FY2026 revenue and other income of AUD 788.7 million.
  • Operating EBITDA rose 30.3% to AUD 164.8 million; the operating margin reached 20.9%.
  • Statutory net profit after tax was AUD 22.0 million; operating net profit was AUD 47.4 million.
  • The group reported operating free cash flow of AUD 106.4 million and year-end leverage of 2.3 times.

Integral Diagnostics Limited provides diagnostic imaging services through community radiology clinics and specialist practices across Australia and New Zealand. Its August 2026 full-year results showed higher reported revenue and earnings alongside integration activity across its clinic network. Integral Diagnostics Limited (ASX:IDX) closed at AUD 2.10 on 20 October 2026, rising 0.48% over the trading session. The closing-price movement is not attributed to the earlier results announcement.

Company Business

The group offers magnetic resonance imaging, computed tomography, ultrasound, X-ray, mammography, nuclear medicine and other diagnostic services. Referrals come from medical practitioners, with examinations delivered by radiologists, sonographers and other clinical employees. Imaging supports diagnosis, treatment planning and ongoing management across a wide range of medical conditions.

Integral Diagnostics (ASX:IDX) operates through established regional imaging brands, including Capital Radiology, Lake Imaging, Apex Radiology, South Coast Radiology and New Zealand practices such as Astra Radiology. Its network creates exposure to Australian medical funding arrangements and New Zealand healthcare demand. The FY2026 annual report recorded 142 clinics, 468 radiologists, more than 1.7 million patients and more than 4.0 million examinations.

Recent Development

The group released its FY2026 results in late August, following preliminary numbers earlier that month. Reported growth reflects a full financial year incorporating the expanded business following the Capitol Health transaction. This distinction matters when comparing periods because the earlier comparative year contained a shorter contribution from those operations.

Integral Diagnostics (ASX:IDX) reported continuing integration activities and a new senior leadership arrangement during 2026. Jason Martinez commenced as managing director and chief executive officer in August. Separately, Sunshine Coast Radiology opened a clinic within Maroochy Private Hospital in August, expanding local imaging capacity.

An Auckland-based Astra Radiology initiative announced in January included collaboration with wellness providers on whole-body scanning services. These clinic and service developments form part of the group’s operating footprint, although separate earnings contributions were not disclosed for every initiative.

Financial Performance and Sector Context

For the year ended 30 June 2026, Integral Diagnostics (ASX:IDX) recorded revenue and other income of AUD 788.7 million, an increase of 25.6%. Operating EBITDA increased 30.3% to AUD 164.8 million, taking the operating EBITDA margin from 20.1% to 20.9%. These are management-defined operating measures and differ from statutory profit.

Operating net profit after tax was AUD 47.4 million, up 50.1%, while statutory net profit after tax was AUD 22.0 million. The company identified AUD 25.4 million of net-of-tax non-operating items, including transaction, restructuring and integration expenses and other adjustments. Operating diluted earnings per share rose 23.6% to 12.6 cents.

Operating free cash flow reached AUD 106.4 million, up 30.7%, while the reported net debt-to-operating-EBITDA ratio declined to 2.3 times from 2.6 times. The board declared a fully franked final dividend of 6.0 cents per share, paid in October, taking FY2026 dividends to 9.3 cents per share.

Diagnostic imaging demand is shaped by clinical referrals, population health needs, practitioner availability, equipment utilisation and government reimbursement settings. For Integral Diagnostics (ASX:IDX), labour costs, scanning capacity and the balance between public funding and patient charges remain relevant operational variables.

Risks to Consider

Integration of a larger clinic network requires consistent information systems, scheduling, procurement and clinical processes. Delays in combining operations could affect costs and service delivery. Radiologist and specialist workforce availability may constrain appointment capacity, while rising employment and equipment expenses can affect margins.

Integral Diagnostics (ASX:IDX) also operates within regulated healthcare systems where changes to reimbursement schedules, accreditation requirements and patient affordability could influence volumes and unit revenue. Debt servicing requirements and capital spending on scanners and clinic facilities must be assessed alongside cash generation.

What to Watch Next

The next scheduled annual general meeting is on 29 October 2026. Shareholders may monitor commentary on integration, staffing, service volumes, clinic openings and financing. The company’s investor calendar lists its next half-year results for February 2027.

For Integral Diagnostics (ASX:IDX), subsequent disclosures on operating margins, free cash flow and net debt will help show whether operational changes are reflected in reported results. Any revisions to dividend policy, capital spending or integration milestones should be assessed against formal announcements.

Key Insights

Integral Diagnostics has reported increased FY2026 revenue, operating earnings and cash flow, with statutory profit remaining below adjusted operating profit. Its enlarged imaging network spans Australia and New Zealand and brings both integration responsibilities and ongoing clinical service demand. The main observable measures are examination activity, workforce capacity, costs, reimbursement conditions and leverage.